COVID-19 and tuberculosis reactivation: a systematic review assessing most common risk factors


  • Sachchidanand Tewari Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India
  • Rahul Yadav Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India



COVID-19, Tuberculosis reactivation, Diabetes, Corticosteroids, Tocilizumab


COVID-19 as a pandemic not only shifted the focus of the healthcare system from other diseases but also affected the disease progression of infections like tuberculosis which remained a leading killer in the past worldwide. COVID-19 itself is said to reactivate latent tuberculosis as shown in animal experiments. Immunomodulators such as corticosteroids and tocilizumab which are being used for covid treatment even further predisposes patients to tuberculosis reactivation and increased progression of the disease. Diabetes is already known to be a risk factor for tuberculosis reactivation and impact tuberculosis progression and worsen the situation. The exact mechanism of interaction of covid-19 and tuberculosis and their effect on each other remains unknown. Considering high prevalence of tuberculosis and the current scenario of covid-19 in world, there is need to study the impact of covid-19 infection on tuberculosis progression or reactivation and commonly associated risk factors. We conducted a systematic search of the online databases to collect data of patients who had tuberculosis reactivation or increased progression of disease after covid-19 infection. Data of a total of 18 patients was retrieved and used for the syntheses of the study. Diabetes was present in 50% of the patients. 55.5% patients were administered corticosteroids for covid-19 treatment later presenting with tuberculosis. Tocilizumab however was administered to 22.2% patients who also received corticosteroids. 27.7% patients suffered tuberculosis reactivation after covid-19 infection without history of diabetes and corticosteroid or tocilizumab administration. None of the patients were reported to have HIV infection. Major risk factors present in patients included corticosteroid administration and diabetes. However, tuberculosis reactivation was seen even in absence of these factors indicating that covid-19 infection may itself be responsible for tuberculosis reactivation. The exact mechanism however remains unknown and further clinical studies are needed to know the same.

Author Biographies

Sachchidanand Tewari, Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India

Assistant Professor,

Department of Pharmacology,

All India Institute of Medical Sciences (AIIMS),

Dalmau Road, Munshiganj,

Raebareli, UP. India. 229405

Rahul Yadav, Department of Pharmacology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India

MBBS Student (6th Semester)


WHO. Listings of WHO’s response to COVID-19, 2020. Available at: Accessed on 10 September 2022.

Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021;27(2):151-65.

Mohareb AM, Rosenberg JM, Bhattacharyya RP, Kotton CN, Chu JT, Jilg N, et al. Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients. J Immigr Minor Health. 2021;23(6):1343-7.

Solá E, Rivera C, Mangual M, Martinez J, Rivera K, Fernandez R. Diabetes mellitus: an important risk factor for reactivation of tuberculosis. Endocrinol Diabetes Metab Case Rep. 2016;2016:16-0035.

Pathak L, Gayan S, Pal B, Talukdar J, Bhuyan S, Sandhya S, et al. Coronavirus Activates an Altruistic Stem Cell-Mediated Defense Mechanism that Reactivates Dormant Tuberculosis: Implications in Coronavirus Disease 2019 Pandemic. Am J Pathol. 2021;191(7):1255-68.

Sasson A, Aijaz A, Chernyavsky S, Salomon N. Pulmonary cavitary tb in a patient with sars cov 2 pneumonia. Chest. 2020;158(4):A560-1.

Garg N, Lee YI. Reactivation tb with severe COVID-19. Chest. 2020;158(4):A777.

Khayat M, Fan H, Vali Y. COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report. Respir Med Case Rep. 2021;32:101344.

Elziny MM, Ghazy A, Elfert KA, Aboukamar M. Case Report: Development of Miliary Pulmonary Tuberculosis in a Patient with Peritoneal Tuberculosis after COVID-19 Upper Respiratory Tract Infection. Am J Trop Med Hyg. 2020;104(5):1792-5.

Lee G, Stoll JJ, Husseini J. A Rare Case of Latent Tuberculosis Reactivation in the Setting of COVID-19 Infection. American J Resp Critical Care Med. 2021;201(9):74.

Liu WD, Wang JT, Hung CC, Chang SC. Accelerated progression of pulmonary tuberculosis in a COVID-19 patient after corticosteroid treatment. J Microbiol Immunol Infect. 2022;55(2):347-9.

Younes I, Noori M, Elkattawy S, Viechweg J, Nwachukwu O. Latent Mycobacterium Tb Reactivation In Two Patients With COVID-19 Pneumonia. Chest. 2021;160(4):A469.

Noh S, Dronavalli G. Active Tb After The Use Of Tocilizumab For COVID-19 Infection. Chest. 2021;160(4):A289.

Pozdnyakov A, Jin A, Bader M. Reactivation of Pulmonary Tuberculosis in a Patient With COVID-19: Case Report and Review of Literature. Infect Dis Clin Pract (Baltim Md). 2021;29(6):468-70.

Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, et al. Invasive Pulmonary Aspergillosis and Tuberculosis Complicated by Hemophagocytic Lymphohistiocytosis - Sequelae of COVID-19 in a Liver Transplant Recipient. J Clin Exp Hepatol. 2022;12(3):1007-11.

Durán GP, Prieto-Martínez E, Ayala D, García J, Thomas JM, García JI, et al. COVID-19 and chronic diabetes: the perfect storm for reactivation tuberculosis?: a case series. J Med Case Rep. 2021;15(1):621.

Iovino M, Caruso M, Corvino A, Vargas N, Sandomenico F, et al. Latent tuberculosis reactivation in the setting of SARS-Cov-2 infection: The analysis of the radiologic features that help the diagnosis. Radiol Case Rep. 2022;17(4):1309-12.

Noori MAM, Younes I, Latif A, Fichadiya H, Elkattawy S, et al. Reactivation of Tuberculosis in the Setting of COVID-19 Infection. Cureus. 2022;14(3):e23417.

Landivar J, Jiménez-Fuentes MA, Souza-Galvão ML. Tuberculosis Reactivation After Severe SARS-COV-2 Pneumonia. Arch Bronconeumol. 2022:S0300-2896(22)00323-4.

Friedman A, DeGeorge KC. Reactivation of latent tuberculosis in a COVID-19 patient on corticosteroid treatment. BMJ Case Rep. 2022;15(5):e247562.




How to Cite

Tewari, S., & Yadav, R. (2022). COVID-19 and tuberculosis reactivation: a systematic review assessing most common risk factors. International Journal of Basic & Clinical Pharmacology, 11(6), 641–645.



Systematic Reviews